Will new therapy for genetic disease alter underwriting practices?
Mount Sinai School of Medicine.
R
R
Desnick
D000818:Animals; D004274:DNA, Recombinant / Q000627:therapeutic use; D057487:Enzyme Therapy; D005544:Forecasting; D030342:Genetic Diseases, Inborn / Q000188:drug therapy*; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D007348:Insurance, Health; D007352:Insurance, Life; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice